Logo image of QNRX

QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Fundamental Analysis

NASDAQ:QNRX - Nasdaq - US74907L4095 - ADR - Currency: USD

8.47  +0.48 (+6.01%)

After market: 8.05 -0.42 (-4.96%)

Fundamental Rating

2

Taking everything into account, QNRX scores 2 out of 10 in our fundamental rating. QNRX was compared to 561 industry peers in the Biotechnology industry. While QNRX seems to be doing ok healthwise, there are quite some concerns on its profitability. QNRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year QNRX has reported negative net income.
In the past year QNRX has reported a negative cash flow from operations.
In the past 5 years QNRX always reported negative net income.
In the past 5 years QNRX always reported negative operating cash flow.
QNRX Yearly Net Income VS EBIT VS OCF VS FCFQNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

QNRX has a Return On Assets (-57.05%) which is comparable to the rest of the industry.
The Return On Equity of QNRX (-97.37%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.05%
ROE -97.37%
ROIC N/A
ROA(3y)-64.6%
ROA(5y)-101.86%
ROE(3y)-126.09%
ROE(5y)-748.48%
ROIC(3y)N/A
ROIC(5y)N/A
QNRX Yearly ROA, ROE, ROICQNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QNRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNRX Yearly Profit, Operating, Gross MarginsQNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, QNRX has more shares outstanding
QNRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, QNRX has an improved debt to assets ratio.
QNRX Yearly Shares OutstandingQNRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
QNRX Yearly Total Debt VS Total AssetsQNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

QNRX has an Altman-Z score of 9.99. This indicates that QNRX is financially healthy and has little risk of bankruptcy at the moment.
QNRX has a better Altman-Z score (9.99) than 86.63% of its industry peers.
QNRX has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of QNRX (0.32) is worse than 72.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z 9.99
ROIC/WACCN/A
WACCN/A
QNRX Yearly LT Debt VS Equity VS FCFQNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

QNRX has a Current Ratio of 3.57. This indicates that QNRX is financially healthy and has no problem in meeting its short term obligations.
QNRX has a Current ratio (3.57) which is in line with its industry peers.
A Quick Ratio of 3.57 indicates that QNRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.57, QNRX is in line with its industry, outperforming 44.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.57
Quick Ratio 3.57
QNRX Yearly Current Assets VS Current LiabilitesQNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

1

3. Growth

3.1 Past

QNRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.80%, which is quite impressive.
EPS 1Y (TTM)80.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, QNRX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.28% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.05%
EPS Next 2Y35.06%
EPS Next 3Y29.28%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNRX Yearly Revenue VS EstimatesQNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
QNRX Yearly EPS VS EstimatesQNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

QNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNRX Price Earnings VS Forward Price EarningsQNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNRX Per share dataQNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as QNRX's earnings are expected to grow with 29.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.06%
EPS Next 3Y29.28%

More info and screens

0

5. Dividend

5.1 Amount

QNRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (5/20/2025, 8:00:01 PM)

After market: 8.05 -0.42 (-4.96%)

8.47

+0.48 (+6.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners18.89%
Inst Owner Change-72.85%
Ins Owners16.57%
Ins Owner Change91.52%
Market Cap174.36M
Analysts82.5
Price Target61.4 (624.91%)
Short Float %N/A
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16%
Min EPS beat(2)6.6%
Max EPS beat(2)25.4%
EPS beat(4)3
Avg EPS beat(4)6.53%
Min EPS beat(4)-43.19%
Max EPS beat(4)37.32%
EPS beat(8)6
Avg EPS beat(8)9.48%
EPS beat(12)9
Avg EPS beat(12)13.78%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3400%
PT rev (3m)1237.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2474.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 18.94
P/tB 19.99
EV/EBITDA N/A
EPS(TTM)-48.85
EYN/A
EPS(NY)-14.28
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0
BVpS0.45
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.05%
ROE -97.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.6%
ROA(5y)-101.86%
ROE(3y)-126.09%
ROE(5y)-748.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.57
Quick Ratio 3.57
Altman-Z 9.99
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.27%
EPS Next Y55.05%
EPS Next 2Y35.06%
EPS Next 3Y29.28%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.09%
OCF growth 3YN/A
OCF growth 5YN/A